HOLOGIC INC's ticker is HOLX and the CUSIP is 436440101. A total of 636 filers reported holding HOLOGIC INC in Q1 2021. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.
About HOLOGIC INC
Hologic Inc: A Leader in Women's Health
Hologic Inc is a medical technology company that specializes in women's health. The company is headquartered in Marlborough, Massachusetts, and has operations in over 50 countries worldwide. Hologic's mission is to improve women's health through early detection and treatment of diseases such as breast cancer, cervical cancer, and osteoporosis.
Hologic's flagship product is the Genius 3D Mammography system, which is the first and only FDA-approved 3D mammography system. The system provides better detection of breast cancer than traditional 2D mammography, and reduces the need for additional imaging and biopsies. Hologic also offers a range of other products for breast cancer screening and diagnosis, including breast biopsy systems and breast MRI coils.
In addition to breast health, Hologic also offers products for cervical cancer screening, such as the ThinPrep Pap test and the Aptima HPV assay. The company also offers products for osteoporosis diagnosis and treatment, including the Horizon DXA system and the Fluoroscan InSight FD mini C-arm.
Hologic has a strong commitment to research and development, with over 1,200 patents and patent applications worldwide. The company invests heavily in clinical studies to ensure the safety and efficacy of its products, and has a team of over 1,000 scientists and engineers working to develop new technologies.
Overall, Hologic is a leader in women's health, with a strong focus on early detection and treatment of diseases. The company's innovative products and commitment to research make it a valuable partner for healthcare providers and patients alike.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $39,187,665 | -15.1% | 527,780 | -10.9% | 0.03% | -9.4% |
| Q1 2024 | $46,177,501 | +7.5% | 592,323 | -1.5% | 0.03% | 0.0% |
| Q4 2023 | $42,960,742 | -3.6% | 601,270 | -6.4% | 0.03% | -13.5% |
| Q3 2023 | $44,579,645 | -15.8% | 642,358 | -1.8% | 0.04% | -9.8% |
| Q2 2023 | $52,966,606 | -12.2% | 654,151 | -12.5% | 0.04% | -8.9% |
| Q1 2023 | $60,328,738 | -25.4% | 747,568 | -30.8% | 0.04% | -29.7% |
| Q4 2022 | $80,823,751 | -2.3% | 1,080,387 | -15.8% | 0.06% | -5.9% |
| Q3 2022 | $82,754,000 | -8.4% | 1,282,607 | -1.6% | 0.07% | -2.9% |
| Q2 2022 | $90,368,000 | +33.2% | 1,304,007 | +47.7% | 0.07% | +55.6% |
| Q1 2022 | $67,828,000 | -11.0% | 882,952 | -11.3% | 0.04% | -2.2% |
| Q4 2021 | $76,225,000 | +1.1% | 995,628 | -2.5% | 0.05% | -2.1% |
| Q3 2021 | $75,372,000 | -13.8% | 1,021,167 | -22.1% | 0.05% | -9.6% |
| Q2 2021 | $87,441,000 | -31.6% | 1,310,562 | -23.8% | 0.05% | -35.0% |
| Q1 2021 | $127,846,000 | +1.2% | 1,718,821 | -1.0% | 0.08% | -2.4% |
| Q4 2020 | $126,392,000 | +19.8% | 1,735,435 | +9.4% | 0.08% | +15.5% |
| Q3 2020 | $105,481,000 | +32.4% | 1,586,894 | +13.5% | 0.07% | +26.8% |
| Q2 2020 | $79,682,000 | +51.3% | 1,397,936 | -6.8% | 0.06% | +24.4% |
| Q1 2020 | $52,669,000 | -14.6% | 1,500,547 | +27.0% | 0.04% | -6.2% |
| Q4 2019 | $61,696,000 | +4.2% | 1,181,687 | +0.8% | 0.05% | -5.9% |
| Q3 2019 | $59,213,000 | +12.5% | 1,172,776 | +7.0% | 0.05% | +8.5% |
| Q2 2019 | $52,651,000 | -4.0% | 1,096,429 | -3.2% | 0.05% | -7.8% |
| Q1 2019 | $54,841,000 | +39.6% | 1,133,076 | +16.6% | 0.05% | +21.4% |
| Q4 2018 | $39,293,000 | +10.0% | 971,389 | +11.4% | 0.04% | +10.5% |
| Q3 2018 | $35,721,000 | +4.9% | 871,667 | +1.8% | 0.04% | -5.0% |
| Q2 2018 | $34,038,000 | +13.1% | 856,292 | +6.3% | 0.04% | +2.6% |
| Q1 2018 | $30,105,000 | -12.4% | 805,797 | +0.2% | 0.04% | -11.4% |
| Q4 2017 | $34,370,000 | +17.5% | 803,987 | +0.8% | 0.04% | +7.3% |
| Q3 2017 | $29,252,000 | -21.4% | 797,261 | -2.8% | 0.04% | -25.5% |
| Q2 2017 | $37,203,000 | +24.9% | 819,806 | +17.1% | 0.06% | +19.6% |
| Q1 2017 | $29,777,000 | +6.1% | 699,811 | +0.1% | 0.05% | 0.0% |
| Q4 2016 | $28,059,000 | +5.8% | 699,372 | +2.4% | 0.05% | +7.0% |
| Q3 2016 | $26,521,000 | +9.1% | 683,007 | -2.8% | 0.04% | +2.4% |
| Q2 2016 | $24,308,000 | -2.5% | 702,536 | -2.8% | 0.04% | -4.5% |
| Q1 2016 | $24,925,000 | -5.5% | 722,452 | +7.8% | 0.04% | -6.4% |
| Q4 2015 | $26,369,000 | +5.8% | 670,273 | +5.2% | 0.05% | -2.1% |
| Q3 2015 | $24,924,000 | +11.3% | 636,943 | +8.3% | 0.05% | +20.0% |
| Q2 2015 | $22,392,000 | +16.3% | 588,339 | +0.9% | 0.04% | +14.3% |
| Q1 2015 | $19,253,000 | +27.1% | 582,995 | +3.6% | 0.04% | +20.7% |
| Q4 2014 | $15,148,000 | +26.1% | 562,818 | +14.0% | 0.03% | +20.8% |
| Q3 2014 | $12,013,000 | -18.8% | 493,750 | -15.4% | 0.02% | -20.0% |
| Q2 2014 | $14,790,000 | +1.4% | 583,427 | -14.0% | 0.03% | -3.2% |
| Q1 2014 | $14,588,000 | -3.9% | 678,514 | -0.2% | 0.03% | 0.0% |
| Q4 2013 | $15,173,000 | +3.4% | 679,772 | -4.3% | 0.03% | -3.1% |
| Q3 2013 | $14,671,000 | +5.5% | 710,453 | -1.4% | 0.03% | 0.0% |
| Q2 2013 | $13,905,000 | – | 720,447 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 500,000 | $28,500,000 | 7.18% |
| Tamarack Advisers, LP | 325,000 | $18,525,000 | 5.16% |
| Otter Creek Advisors, LLC | 89,267 | $5,088,000 | 4.03% |
| Glenview Capital Management | 1,935,735 | $110,337,000 | 3.04% |
| Avidity Partners Management LP | 817,200 | $46,580,000 | 2.99% |
| ATWOOD & PALMER INC | 308,503 | $17,585,000 | 2.38% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,370,186 | $78,101,000 | 2.27% |
| LaFleur & Godfrey LLC | 131,530 | $7,497,000 | 1.91% |
| Sivik Global Healthcare LLC | 100,000 | $5,700,000 | 1.89% |
| PFM Health Sciences, LP | 613,776 | $34,985,000 | 1.82% |